JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Home・Akciju saraksts・Heron Therapeutics Inc

Heron Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

1.21 2.54

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.19

Max

1.24

Galvenie mērījumi
By Trading Economics
Ienākumi	15M -3M
Pārdošana	2.4M 41M
EPS	-0.02
Peļņas marža	-7.278
Darbinieki	128
EBITDA	13M -792K

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+278.15% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 11. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	6.2M 224M
Iepriekšējā atvēršanas cena	-1.33
Iepriekšējā slēgšanas cena	1.21

Ziņu noskaņojums

By Acuity

50%

177 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

2.0001 / 2.42 Atbalsts un pretestība

Heron Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. apr. 23:33 UTC

Karstas akcijas

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

2026. g. 28. apr. 23:24 UTC

Peļņas

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

2026. g. 28. apr. 23:15 UTC

Galvenie ziņu notikumi

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

2026. g. 28. apr. 22:46 UTC

Peļņas

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

2026. g. 28. apr. 22:37 UTC

Peļņas

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

2026. g. 28. apr. 22:15 UTC

Peļņas

Galvenie ziņu notikumi

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

2026. g. 28. apr. 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

2026. g. 28. apr. 23:31 UTC

Peļņas

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

2026. g. 28. apr. 23:31 UTC

Peļņas

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

2026. g. 28. apr. 23:30 UTC

Peļņas

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

2026. g. 28. apr. 23:30 UTC

Peļņas

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

2026. g. 28. apr. 23:19 UTC

Tirgus saruna

Peļņas

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

2026. g. 28. apr. 23:09 UTC

Peļņas

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

2026. g. 28. apr. 23:03 UTC

Tirgus saruna

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

NIESR Sees One Rate Rise to 4% in Benign Scenario

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

2026. g. 28. apr. 23:01 UTC

Galvenie ziņu notikumi

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

2026. g. 28. apr. 22:51 UTC

Peļņas

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

2026. g. 28. apr. 22:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 28. apr. 22:48 UTC

Tirgus saruna

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

2026. g. 28. apr. 22:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

2026. g. 28. apr. 22:32 UTC

Peļņas

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

2026. g. 28. apr. 22:25 UTC

Iegādes, apvienošanās, pārņemšana

Pernod Ricard and Brown-Forman End Deal Talks -- Update

2026. g. 28. apr. 22:22 UTC

Peļņas

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

2026. g. 28. apr. 22:17 UTC

Tirgus saruna

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

2026. g. 28. apr. 22:14 UTC

Peļņas

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

2026. g. 28. apr. 22:14 UTC

Peļņas

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

2026. g. 28. apr. 22:07 UTC

Tirgus saruna

Galvenie ziņu notikumi

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Salīdzinājums

Cenas izmaiņa

Heron Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

278.15% augšup

Prognoze 12 mēnešiem

Vidējais 4.5 USD 278.15%

Augstākais 6 USD

Zemākais 3 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Heron Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Heron Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

2.0001 / 2.42Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

177 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.